Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
STATUS OF THE CLAIMS: Claims 1-20 are pending in this application.
Response to Arguments
Applicant’s arguments, filed May 22, 2026, with respect to the rejection(s) of claims under Claim Rejections - 35 USC § 102 have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground of rejection is made herein below.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by LaRosa et al. (US Pub. 2021/093690).
Applicant claims the following composition:
PNG
media_image1.png
86
640
media_image1.png
Greyscale
PNG
media_image2.png
96
650
media_image2.png
Greyscale
Applicant’s dependent claims 2-19 disclose said compositions comprising various amounts of lanolin, meadowfoam seed oil, squalene, and cannabinoids (THC and CBD).
This reference discloses Applicant’s composition, which is an ointment comprising coconut oil, squalane, and cannabidiol (CBD/THC) in the Abstract and pages 1-88-20. (See Abstract, Examples and entire document). The compositions and method read on the instant claim. Since this reference teaches the exact composition and method, Applicant’s claims are anticipated, and thus, rejected under 35 U.S.C. 102.
Claims 1-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Lupia et al. (WO2021/236748).
Applicant claims the following composition:
PNG
media_image1.png
86
640
media_image1.png
Greyscale
PNG
media_image2.png
96
650
media_image2.png
Greyscale
Applicant’s dependent claims 2-19 disclose said compositions comprising various amounts of lanolin, meadowfoam seed oil, squalene, and cannabinoids (THC and CBD).
This reference discloses Applicant’s composition comprising sunflower oil, hemp oil, plant oils, vegetable oils, lanolin, squalane and at least one selected from the group hemp oil and cannabidiol in the Abstract and pages 2-9. (See Abstract, Examples and entire document). The compositions and method read on the instant claim. Since this reference teaches the exact composition and method, Applicant’s claims are anticipated, and thus, rejected under 35 U.S.C. 102.
Claims 1-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by MINTEL-Universal Skincare Outer Space Renewal Oil (2021).
Applicant claims the following composition:
PNG
media_image1.png
86
640
media_image1.png
Greyscale
PNG
media_image2.png
96
650
media_image2.png
Greyscale
Applicant’s dependent claims 2-19 disclose said compositions comprising various amounts of lanolin, meadowfoam seed oil, squalene, and cannabinoids (THC and CBD).
This reference is a skin care oil and it discloses Applicant’s composition comprising lanolin, squalane and meadowfoam and cannabidiol in the product. The compositions and method read on the instant claim. Since this reference teaches the exact composition and method, Applicant’s claims are anticipated, and thus, rejected under 35 U.S.C. 102.
Claims 1-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by MITEL-Intensive Nourishing Night Cream with Ceramides (August 1, 2022).
Applicant claims the following composition:
PNG
media_image1.png
86
640
media_image1.png
Greyscale
PNG
media_image2.png
96
650
media_image2.png
Greyscale
Applicant’s dependent claims 2-19 disclose said compositions comprising various amounts of lanolin, meadowfoam seed oil, squalene, and cannabinoids (THC and CBD).
This reference is a night cream and it discloses Applicant’s composition comprising lanolin, squalane and meadowfoam and cannabidiol in the product. The compositions and method read on the instant claim. Since this reference teaches the exact composition and method, Applicant’s claims are anticipated, and thus, rejected under 35 U.S.C. 102.
The compositions and method read on the instant claim. Since this reference teaches the exact composition and method, Applicant’s claims are anticipated, and thus, rejected under 35 U.S.C. 102.
Conclusion
Claims 1-20 are pending. Claims 1-20 are rejected. No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is (571)272-2909. The examiner can normally be reached M-F 9am to 5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/PAUL V WARD/Primary Examiner, Art Unit 1622
Prosecution Insights